Bloomberg News

Novartis Sues Sun Over Proposed Generic Zometa, Reclast

July 18, 2012

Swiss drugmaker Novartis AG (NOVN) sued Sun Pharmaceutical Industries Ltd. (SUNP) to block it from selling generic forms of the bone-strengthening medications Zometa and Reclast.

Sun, based in Mumbai, has sought U.S. Food and Drug Administration approval to sell copies, according to a complaint filed July 14 in federal court in Newark, New Jersey. Novartis claims the Sun drugs would infringe its patent, which expires in 2028. Basel-based Novartis requested a court order to block the generic drugs until then.

Novartis reported Zometa sales of $1.49 billion last year and Reclast sales of $613 million.

Uday Baldota and Mira Desai, representatives of Sun, didn’t immediately respond to an e-mail seeking comment on the lawsuit outside regular business hours in India.

The case is Novartis v. Sun Pharmaceuticals, 12-cv-4393, U.S. District Court, District of New Jersey (Newark).

To contact the reporters on this story: David Voreacos in Newark, New Jersey, at dvoreacos@bloomberg.net; Catherine Larkin in Denver at Clarkin4@bloomberg.net.

To contact the editors responsible for this story: Michael Hytha at mhytha@bloomberg.net; Brad Skillman at bskillman@bloomberg.net.


We Almost Lost the Nasdaq
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus